Clinical Practice Patterns in IgA Nephropathy: A Global Questionnaire-Based Survey

Overview

Journal Kidney Int Rep

Publisher Elsevier

Specialty Nephrology

Date 2023 Dec 18

PMID 38106584

Authors

Bhavik Bansal

Amritesh Grewal

Boon Wee Teo

Yuko Shima

Madhivanan Sundaram

Haidong He

Arunkumar Subbiah

Dipankar Bhowmik

Sanjay Kumar Agarwal

Hernan Trimarchi

Soumita Bagchi

Affiliations

Soon will be listed here.

Abstract

Introduction: IgA nephropathy (IgAN) displays ethnic differences in disease phenotype. We aimed to examine how this common disease is managed worldwide.

Methods: An online 2-step questionnaire-based survey was conducted among nephrologists globally focusing on various management strategies used in IgAN.

Results: A total of 422 nephrologists responded to the initial survey and 339 to the follow-up survey. Of the nephrologists, 13.7% do not get MEST-C scores in biopsy reports; 97.2% of nephrologists use renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting-enzyme inhibitors (ACEi) / angiotensin receptor blockers (ARB) as initial treatment. Other supportive treatments commonly employed are fish oil (43.6%) and sodium-glucose co-transporter-2 (SGLT2) inhibitors (48.6%) with regional differences. Immunosuppression is generally (92.4%) initiated when proteinuria >1 g/d persists for ≥3 months.Main considerations for initiating immunosuppression are level of proteinuria (87.9%), estimated glomerular filtration rate (eGFR) decline (78.7%), lack of response to RAAS blockade (57.6%) and MEST-C score (64.9%). Corticosteroids (89.1%) are universally used as first-line immunosuppression; mycophenolate mofetil is commonly used in resistant patients (49.3%). Only 30.4% nephrologist enroll patients with persistent proteinuria >1 g/d in clinical trials. Nephrologists in Europe (63.6%), North America (56.5%), and Australia (63.6%) are more likely to do so compared to South America (31.3%) and Asia (17.2%). Only 8.1% nephrologists in lower-middle income countries (LMICs) enroll patients in clinical trials, though 40% of them are aware of such trials in their nations.

Conclusion: Although most nephrologists agree on common parameters to assess clinical severity of IgAN, use of RAAS blockade, and blood pressure control, there is heterogeneity in use of other supportive therapies and initiation of immunosuppression. There is reluctance to enroll patients in clinical trials with novel treatments, principally in LMICs.

References

Kunter U, Seikrit C, Floege J . Novel agents for treating IgA nephropathy. Curr Opin Nephrol Hypertens. 2023; 32(5):418-426. DOI: 10.1097/MNH.0000000000000902. View

Yagi K, Okada M, Yanagida H, Kuwajima H, Ikeda M, Sugimoto K . Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy. Clin Exp Nephrol. 2004; 7(4):270-4. DOI: 10.1007/s10157-003-0255-x. View

Currie G, Taylor A, Fujita T, Ohtsu H, Lindhardt M, Rossing P . Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016; 17(1):127. PMC: 5015203. DOI: 10.1186/s12882-016-0337-0. View

Mulder N, Zass L, Hamdi Y, Othman H, Panji S, Allali I . African Global Representation in Biomedical Sciences. Annu Rev Biomed Data Sci. 2021; 4:57-81. DOI: 10.1146/annurev-biodatasci-102920-112550. View

Selvaskandan H, Cheung C, Muto M, Barratt J . New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019; 23(5):577-588. PMC: 6469670. DOI: 10.1007/s10157-019-01700-1. View

Hou F, Xie D, Wang J, Xu X, Yang X, Ai J . Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(2):e2254054. DOI: 10.1001/jamanetworkopen.2022.54054. View

Alexander S, Varughese S, Franklin R, Rebekah G, Roy S, Yusuf S . Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort. Kidney Int Rep. 2022; 7(2):305-318. PMC: 8820995. DOI: 10.1016/j.ekir.2021.11.012. View

Liu L, Yang Y, Shi S, Bao Y, Yang C, Zhu S . Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis. 2019; 74(1):15-22. DOI: 10.1053/j.ajkd.2019.01.026. View

Kiryluk K, Freedberg D, Radhakrishnan J, Segall L, Jacobson J, Mathur M . Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review. Kidney360. 2023; 4(8):1112-1122. PMC: 10476677. DOI: 10.34067/KID.0000000000000165. View

10.

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B . Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015; 373(23):2225-36. DOI: 10.1056/NEJMoa1415463. View

11.

Rodrigues J, Haas M, Reich H . IgA Nephropathy. Clin J Am Soc Nephrol. 2017; 12(4):677-686. PMC: 5383386. DOI: 10.2215/CJN.07420716. View

12.

Liu L, Wang L . ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2012; 77(2):119-25. DOI: 10.5414/CN107244. View

13.

Yang D, He L, Peng X, Liu H, Peng Y, Yuan S . The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial. Ren Fail. 2016; 38(2):242-8. DOI: 10.3109/0886022X.2015.1128251. View

14.

Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J . Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022; 388(2):117-127. PMC: 7614055. DOI: 10.1056/NEJMoa2204233. View

15.

Alemayehu C, Mitchell G, Nikles J . Barriers for conducting clinical trials in developing countries- a systematic review. Int J Equity Health. 2018; 17(1):37. PMC: 5863824. DOI: 10.1186/s12939-018-0748-6. View

16.

Zhang H, Barratt J . Is IgA nephropathy the same disease in different parts of the world?. Semin Immunopathol. 2021; 43(5):707-715. DOI: 10.1007/s00281-021-00884-7. View

17.

Wheeler D, Toto R, Stefansson B, Jongs N, Chertow G, Greene T . A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021; 100(1):215-224. DOI: 10.1016/j.kint.2021.03.033. View

18.

Floege J, Barratt J, Coppo R, Lafayette R, Radhakrishnan J, Reich H . International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. Kidney Int Rep. 2022; 7(9):2076-2080. PMC: 9458983. DOI: 10.1016/j.ekir.2022.05.022. View

19.

Suzuki Y, Monteiro R, Coppo R, Suzuki H . The Phenotypic Difference of IgA Nephropathy and its Race/Gender-dependent Molecular Mechanisms. Kidney360. 2022; 2(8):1339-1348. PMC: 8676395. DOI: 10.34067/KID.0002972021. View

20.

Trimarchi H, Barratt J, Cattran D, Cook H, Coppo R, Haas M . Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. DOI: 10.1016/j.kint.2017.02.003. View